Eloxx Pharmaceuticals Inc（ELOX）の財務ELOXEloxx Pharmaceuticals Inc

In the context of the broader market, ELOX competes directly with industry leaders such as ONCY and INKT. With a market capitalization of $50.26M, it holds a significant position in the sector. When comparing efficiency, ELOX's gross margin of N/A stands against ONCY's N/A and INKT's N/A. Such benchmarking helps identify whether Eloxx Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Eloxx Pharmaceuticals reported a net loss of $4.5 million in Q2 2026, translating to a loss of $0.66 per share, which is a significant increase from a net loss of $1.9 million in the same quarter last year. The company's current ratio improved to 3.74, indicating a strong liquidity position.